RSS Achilles Transfers Technology Assets From TRACERx NSCLC Study To AstraZeneca For $12 Mln, Stock Up

Currently reading:
 RSS Achilles Transfers Technology Assets From TRACERx NSCLC Study To AstraZeneca For $12 Mln, Stock Up

Status
Not open for further replies.

Crax Bot

Staff member
Administrator
Amateur
LV
0
Joined
Nov 5, 2021
Threads
10,143
Likes
1,923
Credits
33,567©
Cash
0$
Achilles Therapeutics Plc. (ACHL) announced on Tuesday that they have finalized an agreement to transfer their commercial license for data and samples from the TRACERx Non-Small Cell Lung Cancer study to AstraZeneca Plc. (AZN) for a sum of $12 million.

In addition to this transaction, AstraZeneca will provide sponsorship for the Achilles Material Acquisition Platform. This proprietary initiative has successfully gathered tumor tissue and blood samples from close to 300 cancer patients.

As part of a strategic review, Achilles, a clinical-stage biopharmaceutical company, is also planning a workforce reduction and a downsizing of its board.

At present, shares of Achilles are trading at $1.08 on the Nasdaq, marking an increase of 10.20 percent.

The material has been provided by InstaForex Company - www.instaforex.com
 
Status
Not open for further replies.
Tips

Similar threads

Top Bottom